{"id":"continuos-ceftazidime-avibactam-infusion","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Phlebitis at infusion site"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL44354","moleculeType":"Small molecule","molecularWeight":"546.59"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftazidime is a third-generation cephalosporin that binds to penicillin-binding proteins and disrupts bacterial cell wall synthesis. Avibactam is a non-beta-lactam beta-lactamase inhibitor that protects ceftazidime from degradation by serine beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), AmpC beta-lactamases, and some carbapenemases. Continuous infusion delivery maintains sustained bactericidal concentrations.","oneSentence":"Ceftazidime/avibactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:57.948Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated urinary tract infections (cUTI) including pyelonephritis"},{"name":"Complicated intra-abdominal infections (cIAI)"},{"name":"Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)"},{"name":"Carbapenem-resistant Enterobacteriaceae (CRE) infections"}]},"trialDetails":[{"nctId":"NCT06811727","phase":"PHASE4","title":"CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients","status":"NOT_YET_RECRUITING","sponsor":"Ivan Šitum, MD","startDate":"2025-05-01","conditions":"Severe Infection","enrollment":140}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Continuos ceftazidime/avibactam infusion","genericName":"Continuos ceftazidime/avibactam infusion","companyName":"Ivan Šitum, MD","companyId":"ivan-itum-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ceftazidime/avibactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation. Used for Complicated urinary tract infections (cUTI) including pyelonephritis, Complicated intra-abdominal infections (cIAI), Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}